Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

United Therapeutics (UTHR) Net Cash Flow (2016 - 2026)

United Therapeutics' Net Cash Flow history spans 17 years, with the latest figure at $217.0 million for Q4 2025.

On a quarterly basis, Net Cash Flow rose 51.43% to $217.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$140.1 million, a 128.62% decrease, with the full-year FY2025 number at -$140.1 million, down 128.62% from a year prior.
Net Cash Flow hit $217.0 million in Q4 2025 for United Therapeutics, up from -$253.0 million in the prior quarter.
Over the last five years, Net Cash Flow for UTHR hit a ceiling of $217.0 million in Q4 2025 and a floor of -$306.8 million in Q2 2025.
Historically, Net Cash Flow has averaged $40.9 million across 5 years, with a median of $68.7 million in 2021.
The widest YoY moves for Net Cash Flow: up 1885.71% in 2023, down 431.49% in 2023.
Tracing UTHR's Net Cash Flow over 5 years: stood at -$13.7 million in 2021, then soared by 59.12% to -$5.6 million in 2022, then skyrocketed by 1885.71% to $100.0 million in 2023, then skyrocketed by 43.3% to $143.3 million in 2024, then soared by 51.43% to $217.0 million in 2025.
Business Quant data shows Net Cash Flow for UTHR at $217.0 million in Q4 2025, -$253.0 million in Q3 2025, and -$306.8 million in Q2 2025.